Galapagos NV downgraded to Neutral from Buy at Goldman Sachs. Goldman Sachs analyst Parekh downgraded Galapagos NV to Neutral from Buy, saying he sees a more balanced risk-reward profile for the stock after its 10% outperformance relative to the Dow Jones STOXX Healthcare index SXDP. The analyst also points to the company’s disappointing Cystic Fibrosis update on June 28th while looking ahead to the late-stage readouts for filgotinib’s FINCH2 trial in rheumatoid arthritis and TORTUGA trial in ankylosing spondylitis in Q3 of this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.